Sumitomo Mitsui Trust Holdings Inc. Has $275.19 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sumitomo Mitsui Trust Holdings Inc. lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 9.3% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,074,466 shares of the biopharmaceutical company’s stock after selling 519,626 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.25% of Bristol-Myers Squibb worth $275,188,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of BMY. Northwest Financial Advisors bought a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 553 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $40.06 on Thursday. Bristol-Myers Squibb has a 1 year low of $39.63 and a 1 year high of $65.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The business has a fifty day simple moving average of $42.64 and a two-hundred day simple moving average of $47.97. The company has a market capitalization of $81.21 billion, a P/E ratio of -12.92, a P/E/G ratio of 14.21 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.05 EPS. On average, analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.99%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.